Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. May 8, 2026 Consolidated Financial…
Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy
between this translated document and the Japanese original, the original shall prevail.
May 8, 2026
Consolidated Financial Results
for the Fiscal Year Ended March 31, 2026
(Under Japanese GAAP)
Listed Company: Zeria Pharmaceutical Co., Ltd.
(Stock Exchange: Tokyo Stock Exchange)
Code Number: 4559
(URL: https://www.zeria.co.jp/english/)
Representative: Mitsuhiro Ibe, Representative Director, President & COO
Person in charge of reference: Koichi Tamura, Director, Public Relations Division
TEL (03) 3661-1039
Scheduled date of ordinary general meeting of shareholders: June 26, 2026
Scheduled date to commence dividend payments: June 29, 2026
Scheduled date to submit the Securities Report: June 25, 2026
Preparation of supplementary documents to the financial results:
Yes
Holding of financial results presentation:
Yes (for analysts, institutional investors and the press)
(Amounts under a million yen are truncated.)
- Consolidated Financial Highlights (April 1, 2025 through March 31, 2026)
(Percentage figures indicate changes from the previous year.)
(1) Consolidated Financial Results
Net sales
Year ended
March 31, 2026
March 31, 2025
Million yen
89,159
87,311
Operating profit
%
2.1
15.3
Million yen
12,374
12,197
%
1.4
26.8
Profit attributable to
owners of parent
Million yen
%
8,454
(14.9)
9,936
28.5
Ordinary profit
Million yen
11,043
12,840
%
(14.0)
50.8
Note: Comprehensive income: For the year ended March 31, 2026: 20,926 million yen [75.1%]
For the year ended March 31, 2025: 11,952 million yen [(25.7)%]
Year ended
March 31, 2026
March 31, 2025
Basic earnings
per share
Yen
191.80
225.42
Diluted earnings
per share
Yen
–
–
Ordinary profit
to total assets
Return on equity
%
%
8.5
11.7
6.5
8.3
Operating profit
to net sales
%
13.9
14.0
Reference: Share of profit (loss) of entities accounted for using equity method: For the year ended March 31, 2026: (180) million yen
For the year ended March 31, 2025: (276) million yen
(2) Consolidated Financial Position
Total assets
As of
March 31, 2026
March 31, 2025
Net assets
Million yen
179,697
159,171
Million yen
108,604
89,797
Reference: Equity: As of March 31, 2026: 108,396 million yen
Equity ratio
Net assets per share
%
Yen
2,459.12
2,031.33
60.3
56.3
As of March 31, 2025: 89,539 million yen
(3) Consolidated Cash Flows
Year ended
March 31, 2026
March 31, 2025
Cash flows from
operating activities
Million yen
9,955
12,922
Cash flows from
investing activities
Million yen
(2,701)
(1,050)
Cash flows from
financing activities
Million yen
(5,933)
(7,756)
Cash and cash equivalents
at the end of term
Million yen
27,635
23,467
- Dividends
Annual dividends
Year ended
March 31,
2025
March 31,
2026
Year ending
March 31, 2027
(Forecast)
First
quarter
Yen
Second
quarter
Yen
Third
quarter
Yen
–
23.00
–
–
Year-end
Total
Total
dividends paid
(Total)
Payout ratio
(Consolidated)
Dividend rate
for net assets
(Consolidated)
Yen
Yen
Million yen
%
%
–
24.00
47.00
2,071
20.8
2.4
24.00
–
25.00
49.00
2,159
25.5
2.2
25.00
–
25.00
50.00
22.0
- Consolidated Financial Forecast for Fiscal Year Ending March 31, 2027 (April 1, 2026 through March 31, 2027)
Net sales
First six months
Full year
Million yen
45,000
95,000
%
12.6
6.6
(Percentage figures indicate changes from the same period of the previous year.)
Basic
Profit attributable to
Operating profit
Ordinary profit
earnings per
owners of parent
share
Million yen
%
Million yen
%
Million yen
%
Yen
6,000
64.8
6,000
125.9
4,000
130.2
90.75
13,000
5.1
13,000
17.7
10,000
18.3
226.86
- Notes
(1) Significant changes in the scope of consolidation during the period: Yes
Inclusion: – (Company name: –)
Exclusion: 1 Company (Company name: Kenso-Seiyaku Co., Ltd.)
Note: For details, please refer to “3. Consolidated Financial Statements and Significant Notes Thereto, (5) Notes to consolidated
financial statements (Significant matters that form the basis for the preparation of consolidated financial statements)” on
page 13 of the Attached Material.
(2) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements after
error corrections
- Changes in accounting policies due to revisions to accounting standards and other regulations: None
- Changes in accounting policies due to other reasons: None
- Changes in accounting estimates: None
- Restatement of prior period financial statements after error corrections: None
(3) Number of shares issued (common shares)
- Number of shares issued as of the end of the term (including treasury shares):
As of March 31, 2026: 50,119,190 shares As of March 31, 2025: 53,119,190 shares
- Number of shares of treasury shares as of the end of the term:
As of March 31, 2026: 6,039,792 shares
As of March 31, 2025: 9,039,667 shares
- Average number of shares during the term:
For the year ended March 31, 2026: 44,079,460 shares
For the year ended March 31, 2025: 44,079,600 shares
Notes: 1. Based on the resolution at a meeting of the Board of Directors held on August 5, 2025, the Company cancelled
1,000,000 treasury shares as of August 27, 2025.
- Based on the resolution at a meeting of the Board of Directors held on November 5, 2025, the Company cancelled
1,000,000 treasury shares as of November 26, 2025.
- Based on the resolution at a meeting of the Board of Directors held on February 5, 2026, the Company cancelled
1,000,000 treasury shares as of February 25, 2026.
Reference: Summary of Non-consolidated Financial Results
Non-consolidated Financial Highlights (April 1, 2025 through March 31, 2026)
(1) Non-consolidated Financial Results
(Percentage figures indicate changes from the previous year.)
Net sales
Year ended
March 31, 2026
March 31, 2025
Operating profit
Million yen
35,622
34,710
%
2.6
2.0
Basic earnings
per share
Year ended
March 31, 2026
March 31, 2025
Million yen
444
1,269
Ordinary profit
%
(65.0)
7.9
Million yen
3,247
3,422
Profit
%
(5.1)
27.4
Million yen
2,973
2,859
%
4.0
74.7
Diluted earnings
per share
Yen
67.46
64.86
Yen
–
–
(2) Non-consolidated Financial Position
Total assets
As of
March 31, 2026
March 31, 2025
Million yen
91,682
90,023
Reference: Equity: As of March 31, 2026: 42,835 million yen
Net assets
Million yen
42,835
41,016
Equity ratio
Net assets per share
%
46.7
45.6
Yen
971.78
930.52
As of March 31, 2025: 41,016 million yen
- Financial Results Reports Are Exempt From Audit Conducted by Certified Public Accountants or An Audit
Corporation.
- Cautionary Statement with Respect to Appropriate Use of Financial Forecast and Other Special Matters
The description about the future including the projection in this document is based on information available to the Company
at present and certain presumptions which the Company considers reasonable. Consequently, any descriptions herein do not
constitute assurances regarding actual results by the Company. The actual results for future terms may differ from the
information in this document due to various factors. For the assumptions made in financial forecasts and cautions concerning
the use thereof, please refer to “1. Summary of Business Results (1) Summary of business results for the fiscal year under
review” on page 2 of the Attached Material.
○Table of contents of attachments
- Summary of Business Results ...................................................................................................................2
(1) Summary of business results for the fiscal year under review ............................................................2
(2) Overview of financial position for the fiscal year under review .........................................................4
(3) Basic policy on profit distribution and dividends for the fiscal year under review
and the following fiscal year ...............................................................................................................5
- Basic Policy on Selection of Accounting Standards..................................................................................5
- Consolidated Financial Statements and Significant Notes Thereto...........................................................6
(1) Consolidated balance sheet .................................................................................................................6
(2) Consolidated statement of income and consolidated statement of comprehensive
income ................................................................................................................................................8
Consolidated statement of income ......................................................................................................8
Consolidated statement of comprehensive income .............................................................................9
(3) Consolidated statement of changes in equity ....................................................................................10
(4) Consolidated statement of cash flows ...............................................................................................12
(5) Notes to consolidated financial statements .......................................................................................13
(Notes on premise of a going concern) .............................................................................................13
(Significant matters that form the basis for the preparation of consolidated financial statements) ..13
(Notes on segment information, etc.)................................................................................................17
(Notes on per share information) ......................................................................................................21
(Notes on significant subsequent events) ..........................................................................................21
- Supplemental Information .......................................................................................................................22
(1) Sales of major products and merchandise Consolidated ...................................................................22
(2) Status of pipeline of new drugs.........................................................................................................23
1
- Summary of Business Results
(1) Summary of business results for the fiscal year under review
(i) Business results for the fiscal year under review
Net sales for the current fiscal year were 89,159 million yen (up 2.1% from the previous fiscal year), and
operating profit was 12,374 million yen (up 1.4% from the previous year). Ordinary profit was 11,043
million yen (down 14.0% from the previous year), due to a turnaround from foreign exchange gains
recorded in the previous fiscal year to foreign exchange losses in the current fiscal year, and profit
attributable to owners of parent was 8,454 million yen (down 14.9% from the previous year).
In the current fiscal year, the overseas sales to net sales ratio was 59.3%, compared with 56.9% in the
previous fiscal year.
Below are the results by business segment.
(Ethical Pharmaceuticals Business)
As for our mainstay products, Asacol, a therapeutic agent for ulcerative colitis, sales declined through the
third quarter due to challenges in the domestic market and supply shortages caused by malfunctions at the
production facilities to which we outsource manufacturing in overseas markets. However, full-year sales
increased, driven in part by strong performance in overseas markets following the restoration and
normalization of those production facilities. Sales of DIFICLIR, a therapeutic agent for Clostridioides
difficile infections (domestic brand name: Dafclir), continued to grow, particularly in large markets such
as France and Germany. However, sales of Entocort, an inflammatory bowel disease therapeutic agent
(domestic brand name: Zentacort), declined in part due to the launch of generic drugs in certain countries
outside Japan. Sales of Acofide, a drug for functional dyspepsia, increased year on year as market
penetration grew, although they were affected by NHI drug price revisions.
In addition, the Company is striving for the early market penetration of Veltassa, a therapeutic agent for
hyperkalemia, for which restrictions on medication periods were lifted in December 2025, primarily in the
nephrology, dialysis, and cardiology domains.
As a result, net sales in the business amounted to 61,625 million yen (up 4.5% from the previous fiscal
year).
(Consumer Healthcare Business)
As for our mainstay products, the Hepalyse range continued to perform well, mainly in the pharmaceutical
Hepalyse range, due in part to the effects of active advertising and sales promotion activities. In addition,
the new products launched in the fiscal year under review, Hepalyse Gastrointestinal Oral Liquid EX and
Hepalyse Gastrointestinal Drink, have also contributed to sales as they have penetrated the market. On the
other hand, sales of the Chondroitin range and the WithOne range of botanical laxative products decreased
in part due to the impact of competing products.
As a result, net sales in the business amounted to 27,382 million yen (down 2.8% from the previous fiscal
year).
(Other Business)
Net sales in this segment amounted to 150 million yen (down 6.1% from the previous fiscal year), mainly
due to insurance agency business and real estate lease revenue.
2
(Status of Research and Development)
In the Research and Development division, Zeria is carefully selecting development themes and
proceeding with the evaluation of multiple projects including in-licensed, centered on the priority
gastrointestinal field under a global development structure in coordination with our Swiss subsidiary
Tillotts Pharma AG. In this context, we are considering research and development of new development
themes that can be developed simultaneously in Japan and Europe.
As for Z-100, we have been steadily advancing non-clinical trials to facilitate the clinical development for
new indications and have started a new specified clinical trial in patients with lung cancer.
Regarding Z-338 (generic name: Acotiamide), our original product for the indication of functional
dyspepsia, out-licensed FAES FARMA, S.A., has newly obtained approval in Nicaragua and Costa Rica.
Pharmaceutical Joint Stock Company of February 3rd, our subsidiary in Vietnam, has filed an application
for approval in Vietnam. Furthermore, the Company is promoting global development by concluding a
development and sales agreement with Agastra-Lab s.r.l. for Europe, the U.S., and Canada. In Japan,
participant recruitment for the Phase III trial in pediatric patients has been completed, and we are
currently working on compiling the trial results.
The Phase II trial of ZG-802 for the indication of underactive bladder has been completed, and we are
currently exploring options for the next phase.
With regard to Ferinject, an iron deficiency anemia treatment in-licensed from CSL Vifor, we conducted
multiple database studies using real-world data and provided support for specified clinical trials, thereby
enhancing post-marketing evidence and promoting drug development activities.
We have also begun planning and reviewing initiatives to generate evidence for Veltassa, a therapeutic
agent for hyperkalemia in-licensed from CSL Vifor, and are promoting drug development activities to
provide new evidence as soon as possible.
As for consumer healthcare products, we have been developing distinctive products to attract new
customer bases. In the fiscal year ended March 31, 2026, we launched Hepalyse Gastrointestinal Oral
Liquid EX and Hepalyse Gastrointestinal Drink in the Hepalyse series, IONA f Night Wrapping Pack and
IONA R Double Action Cream in the IONA basic skincare series, as well as Hepalyse WT and Chondro
support active for Taiwan, as new products.
As a result of these activities, research and development expenses for the current fiscal year were 3,709
million yen (down 9.7% from the previous fiscal year).
(ii) Future outlook
For the fiscal year ending March 31, 2027, we forecast net sales of 95,000 million yen (up 6.6% from the
previous year), operating profit of 13,000 million yen (up 5.1% from the previous year), ordinary profit of
13,000 million yen (up 17.7% from the previous year), and profit attributable to owners of parent of
10,000 million yen (up 18.3% from the previous year).
Net sales
In the Ethical Pharmaceuticals Business, the Company forecasts that sales will increase, with sales growth
expected in the overseas market for main products Asacol and DIFICLIR, as well as sales growth in Japan
expected for Veltassa, a therapeutic agent for hyperkalemia. In the Consumer Healthcare Business, the
Company expects sales to increase, contributed to by sales growth in the Hepalyse range as well as a
recovery in sales of the mainstay products, such as the Chondroitin range and the WithOne range, and
contributions from product groups following the mainstay products.
Profit
Although we anticipate the impact of soaring energy and raw material prices and increased expenses, such
as R&D expenses, we expect profits to increase as a result of higher sales. Note that while we recorded
foreign exchange losses in non-operating expenses in the fiscal year ended March 31, 2026, we do not
3
anticipate any foreign exchange gains or losses in the fiscal year ending March 31, 2027. Consequently,
the growth rates for ordinary profit and profit attributable to owners of parent are expected to exceed the
growth rate for operating profit.
(2) Overview of financial position for the fiscal year under review
(i) Assets, liabilities, and net assets
Total assets at the end of the current fiscal year were 179,697 million yen, an increase of 20,526 million
yen from the end of the previous fiscal year. Current assets increased 13,117 million yen to 82,646 million
yen from the end of the previous fiscal year, and non-current assets increased 7,409 million yen to 97,051
million yen from the end of the previous fiscal year. The main changes in current assets included increases
of 4,167 million yen in cash and deposits, 4,915 million yen in accounts receivable - trade, and 4,462
million yen in inventories such as merchandise and finished goods. The main change in non-current assets
was an increase of 7,231 million yen in investments and other assets.
Total liabilities at the end of the current fiscal year were 71,093 million yen, an increase of 1,718 million
yen from the end of the previous fiscal year. Current liabilities increased 1,259 million yen to 55,708
million yen from the end of the previous fiscal year, and non-current liabilities increased 459 million yen
to 15,385 million yen from the end of the previous fiscal year. The main changes in current liabilities were
an increase of 924 million yen in accounts payable - trade, a decrease of 464 million yen in short-term
borrowings, an increase of 1,054 million yen in income taxes payable, and a decrease of 410 million yen
in other current liabilities including a decrease in accounts payable - other. The main change in noncurrent liabilities was a decrease of 1,596 million yen in long-term borrowings and an increase of 2,090
million yen in deferred tax liabilities.
Net assets at the end of the current fiscal year were 108,604 million yen, an increase of 18,807 million yen
from the end of the previous fiscal year. This was mainly due to profit attributable to owners of parent of
8,454 million yen, payment of 2,115 million yen as dividends declared at the end of the previous fiscal
year and in the current interim period, an increase of 7,632 million yen in foreign currency translation
adjustment, and an increase of 3,927 million yen in remeasurements of defined benefit plans.
As a result, equity ratio at the end of the current fiscal year increased by 4.0 percentage points from the
end of the previous fiscal year to 60.3%.
(ii) Status of cash flows
Cash and cash equivalents (below, “cash”) at the end of the fiscal year under review increased 4,167
million yen from the beginning of the period to 27,635 million yen. This was due to net cash provided by
operating activities of 9,955 million yen, despite net cash used in investing activities of 2,701 million yen
and net cash used in financing activities of 5,933 million yen.
The status of each cash flow and its factors for the fiscal year under review are as follows.
[Net cash provided by (used in) operating activities]
Net cash provided by operating activities amounted to 9,955 million yen in the current fiscal year (down
2,966 million yen from the previous fiscal year). This was due to factors including profit before income
taxes of 11,200 million yen, depreciation of 6,629 million yen, an increase in trade receivables of 1,896
million yen, an increase in inventories of 3,423 million yen, and income taxes paid of 2,737 million yen.
[Net cash provided by (used in) investing activities]
Net cash used in investing activities totaled 2,701 million yen in the current fiscal year (down 1,650
million yen from the previous fiscal year). This was due mainly to purchase of property, plant and
equipment of 2,360 million yen and purchase of intangible assets of 534 million yen.
4
[Net cash provided by (used in) financing activities]
Net cash used in financing activities totaled 5,933 million yen in the current fiscal year (up 1,823 million
yen from the previous fiscal year). This was mainly due to proceeds from long-term borrowings of 1,150
million yen, repayments of long-term borrowings of 4,533 million yen, and dividends paid of 2,109
million yen.
Trends in cash flow-related indicators
Fiscal year ended
March 31, 2024
Fiscal year ended
March 31, 2025
Fiscal year ended
March 31, 2026
Equity ratio (%)
52.9
56.3
60.3
Equity ratio based on market
value (%)
62.4
62.5
53.8
Ratio of interest-bearing debt to
cash flow (years)
3.9
3.3
4.1
Interest coverage ratio (times)
27.3
26.3
20.0
(Notes) 1. Each indicator is calculated as follows.
(i)
Equity ratio: equity/total assets
(ii) Equity ratio based on market value: market capitalization/total assets
(iii) Ratio of interest-bearing debt to cash flow: interest-bearing debt/cash flow
(iv) Interest coverage ratio: cash flow/interest payments
2. All of the above ratios are calculated based on consolidated financial figures.
3. Market capitalization is calculated based on the number of shares issued excluding treasury shares.
4. Operating cash flow is used for cash flow calculations.
5. Interest-bearing debt includes all liabilities on the consolidated balance sheets for which interest is paid.
(3) Basic policy on profit distribution and dividends for the fiscal year under review and the following fiscal
year
The Company considers the return of profit to shareholders as one of its most important management issues,
and our basic profit distribution policy is to pay stable and consistent dividends.
Based on a full consideration of the financial results and other factors, we will pay a year-end dividend for the
fiscal year under review of 25 yen per share. Accordingly, we intend to pay an annual dividend of 49 yen,
including an interim dividend of 24 yen (an increase of 2 yen compared to the annual dividend for the
previous fiscal year).
For the next fiscal year, we are planning for an annual dividend of 50 yen per share (an increase of 1 yen
compared to the fiscal year under review), including a dividend of 25 yen per share for both the interim and
year-end dividend.
- Basic Policy on Selection of Accounting Standards
In order to ensure comparability among companies and over time, the Group applies Japanese GAAP for
accounting standards.
It is the Company’s policy to apply International Financial Reporting Standards in an appropriate manner,
taking into consideration various domestic and overseas circumstances.
5
- Consolidated Financial Statements and Significant Notes Thereto
(1) Consolidated balance sheet
(Thousands of yen)
As of March 31, 2025
Assets
Current assets
Cash and deposits
Notes receivable - trade
Electronically recorded monetary claims - operating
Accounts receivable - trade
Merchandise and finished goods
Work in process
Raw materials and supplies
Other
Allowance for doubtful accounts
Total current assets
Non-current assets
Property, plant and equipment
Buildings and structures
Accumulated depreciation
Buildings and structures, net
Machinery, equipment and vehicles
Accumulated depreciation
Machinery, equipment and vehicles, net
Land
Construction in progress
Other
Accumulated depreciation
Other, net
Total property, plant and equipment
Intangible assets
Goodwill
Sales right
Trademark right
Other
Total intangible assets
Investments and other assets
Investment securities
Deferred tax assets
Retirement benefit asset
Other
Allowance for doubtful accounts
Total investments and other assets
Total non-current assets
Total assets
6
As of March 31, 2026
23,592,676
243,962
–
26,498,203
8,592,660
2,352,119
5,489,107
2,892,079
(131,114)
69,529,694
27,760,027
–
35,486
31,413,406
10,994,264
3,551,515
6,351,030
3,200,118
(658,965)
82,646,882
26,531,377
(19,913,607)
6,617,770
16,800,871
(15,147,512)
1,653,359
12,658,498
3,617,496
7,458,612
(5,364,292)
2,094,319
26,641,444
27,941,819
(20,835,015)
7,106,803
18,657,215
(15,726,455)
2,930,759
12,663,993
2,905,397
8,062,076
(6,069,647)
1,992,428
27,599,383
3,621,171
27,950,775
7,641,312
1,148,423
40,361,683
3,027,507
27,088,898
7,821,831
1,643,550
39,581,788
8,865,571
97,940
13,264,717
443,262
(32,717)
22,638,773
89,641,902
159,171,596
10,112,376
84,760
19,294,530
407,314
(29,086)
29,869,895
97,051,067
179,697,949
(Thousands of yen)
As of March 31, 2025
Liabilities
Current liabilities
Accounts payable - trade
Short-term borrowings
Income taxes payable
Provision for bonuses
Other
Total current liabilities
Non-current liabilities
Long-term borrowings
Deferred tax liabilities
Retirement benefit liability
Asset retirement obligations
Other
Total non-current liabilities
Total liabilities
Net assets
Shareholders’ equity
Share capital
Capital surplus
Retained earnings
Treasury shares
Total shareholders’ equity
Accumulated other comprehensive income
Valuation difference on available-for-sale securities
Foreign currency translation adjustment
Remeasurements of defined benefit plans
Total accumulated other comprehensive income
Non-controlling interests
Total net assets
Total liabilities and net assets
7
As of March 31, 2026
3,971,467
34,298,379
3,773,088
1,623,664
10,782,461
54,449,062
4,895,991
33,834,190
4,827,849
1,778,324
10,371,773
55,708,129
6,865,780
6,496,077
224,138
56,451
1,283,058
14,925,506
69,374,568
5,269,740
8,586,947
201,368
56,629
1,270,343
15,385,029
71,093,159
6,593,398
11,685,121
67,207,063
(18,266,472)
67,219,110
6,593,398
5,620,541
73,545,791
(12,204,622)
73,555,108
2,108,422
16,995,687
3,216,617
22,320,727
257,189
89,797,027
159,171,596
3,069,779
24,628,069
7,143,784
34,841,632
208,048
108,604,790
179,697,949
(2) Consolidated statement of income and consolidated statement of comprehensive income
Consolidated statement of income
(Thousands of yen)
Fiscal year ended
March 31, 2025
Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating profit
Non-operating income
Interest income
Dividend income
Foreign exchange gains
Other
Total non-operating income
Non-operating expenses
Interest expenses
Foreign exchange losses
Share of loss of entities accounted for using equity
method
Other
Total non-operating expenses
Ordinary profit
Extraordinary income
Gain on sale of non-current assets
Gain on sale of investment securities
Total extraordinary income
Extraordinary losses
Loss on sale of non-current assets
Loss on retirement of non-current assets
Loss on valuation of investment securities
Total extraordinary losses
Profit before income taxes
Income taxes - current
Income taxes - deferred
Total income taxes
Profit
Profit (loss) attributable to non-controlling interests
Profit attributable to owners of parent
8
Fiscal year ended
March 31, 2026
87,311,137
23,351,451
63,959,685
51,762,100
12,197,585
89,159,262
23,976,621
65,182,640
52,808,195
12,374,444
282,871
340,650
634,498
244,784
1,502,805
111,810
366,366
–
302,001
780,178
452,290
–
501,799
1,356,089
276,717
180,435
130,516
859,524
12,840,865
73,044
2,111,369
11,043,254
2,893
–
2,893
417
168,398
168,815
754
15,716
208,673
225,145
12,618,613
2,663,209
(12,601)
2,650,608
9,968,005
31,682
9,936,323
2,075
9,881
–
11,956
11,200,113
3,179,573
(396,599)
2,782,973
8,417,139
(37,404)
8,454,544
Consolidated statement of comprehensive income
(Thousands of yen)
Fiscal year ended
March 31, 2025
Profit
Other comprehensive income
Valuation difference on available-for-sale securities
Foreign currency translation adjustment
Remeasurements of defined benefit plans, net of tax
Total other comprehensive income
Comprehensive income
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
Comprehensive income attributable to non-controlling
interests
9
Fiscal year ended
March 31, 2026
9,968,005
8,417,139
106,850
2,354,646
(477,032)
1,984,464
11,952,469
961,357
7,621,224
3,927,166
12,509,748
20,926,888
11,901,523
20,975,449
50,946
(48,561)
(3) Consolidated statement of changes in equity
Fiscal year ended March 31, 2025
(Thousands of yen)
Shareholders’ equity
Balance at beginning of
period
Share capital
Capital surplus
Retained earnings
Treasury shares
Total shareholders’
equity
6,593,398
11,685,121
59,254,325
(18,265,810)
59,267,035
Changes during period
Dividends of surplus
(1,983,585)
(1,983,585)
Profit attributable to
owners of parent
9,936,323
9,936,323
Purchase of treasury
shares
(662)
(662)
Net changes in items other
than shareholders’ equity
Total changes during period
Balance at end of period
–
–
7,952,737
(662)
7,952,075
6,593,398
11,685,121
67,207,063
(18,266,472)
67,219,110
Accumulated other comprehensive income
Valuation
difference on
available-forsale securities
Balance at beginning of
period
2,001,571
Foreign currency Remeasurements
translation
of defined benefit
adjustment
plans
14,660,305
3,693,650
Total
accumulated
other
comprehensive
income
20,355,527
Non-controlling
interests
Total net assets
206,229
79,828,792
Changes during period
Dividends of surplus
(1,983,585)
Profit attributable to
owners of parent
9,936,323
Purchase of treasury
shares
(662)
Net changes in items other
than shareholders’ equity
Total changes during period
Balance at end of period
106,850
2,335,382
(477,032)
1,965,200
50,959
2,016,160
106,850
2,335,382
(477,032)
1,965,200
50,959
9,968,235
2,108,422
16,995,687
3,216,617
22,320,727
257,189
89,797,027
10
Fiscal year ended March 31, 2026
(Thousands of yen)
Shareholders’ equity
Balance at beginning of
period
Share capital
Capital surplus
Retained earnings
Treasury shares
Total shareholders’
equity
6,593,398
11,685,121
67,207,063
(18,266,472)
67,219,110
Changes during period
Dividends of surplus
(2,115,816)
(2,115,816)
Profit attributable to
owners of parent
8,454,544
8,454,544
Purchase of treasury
shares
Cancellation of treasury
shares
Change in ownership
interest of parent due to
transactions with noncontrolling interests
(6,062,108)
(258)
(258)
6,062,108
–
(2,471)
(2,471)
Net changes in items other
than shareholders’ equity
Total changes during period
Balance at end of period
–
(6,064,580)
6,338,728
6,061,850
6,335,998
6,593,398
5,620,541
73,545,791
(12,204,622)
73,555,108
Accumulated other comprehensive income
Valuation
difference on
available-forsale securities
Balance at beginning of
period
2,108,422
Foreign currency Remeasurements
translation
of defined benefit
adjustment
plans
16,995,687
3,216,617
Total
accumulated
other
comprehensive
income
22,320,727
Non-controlling
interests
Total net assets
257,189
89,797,027
Changes during period
Dividends of surplus
(2,115,816)
Profit attributable to
owners of parent
8,454,544
Purchase of treasury
shares
Cancellation of treasury
shares
Change in ownership
interest of parent due to
transactions with noncontrolling interests
Net changes in items other
than shareholders’ equity
Total changes during period
Balance at end of period
(258)
–
(2,471)
961,357
7,632,381
3,927,166
12,520,905
(49,140)
12,471,764
961,357
7,632,381
3,927,166
12,520,905
(49,140)
18,807,762
3,069,779
24,628,069
7,143,784
34,841,632
208,048
108,604,790
11
(4) Consolidated statement of cash flows
(Thousands of yen)
Fiscal year ended
March 31, 2025
Cash flows from operating activities
Profit before income taxes
Depreciation
Amortization of goodwill
Increase (decrease) in allowance for doubtful accounts
Increase (decrease) in provision for bonuses
Increase (decrease) in retirement benefit liability
Interest and dividend income
Interest expenses
Foreign exchange losses (gains)
Share of loss (profit) of entities accounted for using
equity method
Loss (gain) on sale of investment securities
Loss (gain) on valuation of investment securities
Decrease (increase) in trade receivables
Decrease (increase) in inventories
Increase (decrease) in trade payables
Decrease (increase) in other current assets
Increase (decrease) in other current liabilities
Decrease (increase) in retirement benefit asset
Other, net
Subtotal
Interest and dividends received
Interest paid
Income taxes paid
Net cash provided by (used in) operating activities
Cash flows from investing activities
Payments into time deposits
Proceeds from withdrawal of time deposits
Purchase of property, plant and equipment
Purchase of intangible assets
Proceeds from sale of investment securities
Other payments
Other proceeds
Net cash provided by (used in) investing activities
Cash flows from financing activities
Net increase (decrease) in short-term borrowings
Proceeds from long-term borrowings
Repayments of long-term borrowings
Repayments of lease liabilities
Purchase of treasury shares
Dividends paid
Dividends paid to non-controlling interests
Net cash provided by (used in) financing activities
Effect of exchange rate change on cash and cash
equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
12
Fiscal year ended
March 31, 2026
12,618,613
6,843,170
711,521
(54,973)
644
47,812
(623,522)
452,290
(362,710)
11,200,113
6,629,288
717,902
466,649
29,283
(23,171)
(478,176)
501,799
(40,217)
276,717
180,435
–
208,673
(4,800,944)
(1,647,358)
567,039
(330,072)
662,219
(881,765)
104,254
13,791,609
623,494
(492,007)
(1,001,049)
12,922,046
(168,398)
–
(1,896,310)
(3,423,166)
520,636
(668,928)
(304,286)
(580,987)
51,458
12,713,924
477,862
(498,401)
(2,737,763)
9,955,621
(125,000)
1,787,659
(1,429,102)
(1,304,800)
–
(310)
20,668
(1,050,885)
(125,000)
125,000
(2,360,986)
(534,750)
174,000
(1,333)
21,293
(2,701,776)
(143,500)
3,273,000
(8,515,015)
(393,767)
(662)
(1,976,755)
–
(7,756,699)
7,490
1,150,000
(4,533,050)
(445,090)
(258)
(2,109,398)
(2,717)
(5,933,023)
749,071
2,846,529
4,863,532
18,604,144
23,467,676
4,167,350
23,467,676
27,635,027
(5) Notes to consolidated financial statements
(Notes on premise of a going concern)
Not applicable.
(Significant matters that form the basis for the preparation of consolidated financial statements)
1 Scope of consolidation
(A) Number of consolidated subsidiaries: 17
Tillotts Pharma AG
Tillotts Pharma AB
Tillotts Pharma Ltd.
Tillotts Pharma UK Ltd.
Tillotts Pharma Czech s.r.o.
Tillotts Pharma Spain S.L.U.
Tillotts Pharma GmbH
Tillotts Pharma France SAS
Tillotts Pharma Italy srl
Pharmaceutical Joint Stock Company of February 3rd
ZPD A/S
Zeria Healthway Co., Ltd.
IONA INTERNATIONAL CORPORATION
Zevice Co., Ltd.
Zeriap Co., Ltd.
Two other consolidated subsidiaries
During the fiscal year under review, Kenso-Seiyaku Co., Ltd., the Company’s consolidated subsidiary
was excluded from the scope of consolidation as it was dissolved in an absorption-type merger with
the Company as the surviving company.
(B) Major non-consolidated subsidiaries
Zeria Shoji Co., Ltd.
Zeria Ecotech Co., Ltd.
Non-consolidated subsidiaries are excluded from the scope of consolidation because they are small
companies and their combined total assets, net sales, net income or loss, and retained earnings do not
have a material impact on the consolidated financial statements.
2
Application of equity method
(A) Number of non-consolidated subsidiaries and affiliates accounted for by the equity method: 1
Mage Biologics Inc.
There are no non-consolidated subsidiaries accounted for by the equity method.
(B) Names of major non-consolidated subsidiaries not accounted for by the equity method
Zeria Shoji Co., Ltd.
Zeria Ecotech Co., Ltd.
Non-consolidated subsidiaries not accounted for by the equity method are excluded from the scope of
equity method because their net income and retained earnings have a minimal effect on the
consolidated financial statements and they are insignificant in the aggregate.
(C) For Mage Biologics Inc., an equity-method affiliate, the financial statements for the most recent fiscal
year of the company are used because its fiscal year ends on a different date from the consolidated
fiscal year-end.
3
Fiscal year of consolidated subsidiaries
Of the consolidated subsidiaries, Tillotts Pharma AG, Pharmaceutical Joint Stock Company of February
3rd, ZPD A/S, and other overseas consolidated subsidiaries have a fiscal year ending December 31.
In preparing the consolidated financial statements, the financial statements of these subsidiaries as of
their fiscal year-end are used. However, adjustments necessary for consolidation are made for significant
transactions that occurred between January 1 and March 31, the end of the consolidated fiscal year.
13
4
Matters related to accounting policies
(A) Valuation standards and methods for significant assets
(1) Investment securities
Other securities
Other than stocks and other securities without market price
······ Market value method (unrealized gains or losses are reported as a separate component of
net assets, and the cost of securities sold is determined by the moving-average method)
Stocks and other securities without market price
······ Cost method based on the moving-average method
(2) Derivatives
······ Market value method
(3) Inventories
······ Mainly stated at cost determined by the weighted average method (the carrying value on the
balance sheet is written down to reflect the effect of lower profit margins)
(B) Depreciation and amortization method for significant depreciable assets
(1) Property, plant and equipment (excluding leased assets)
The straight-line method is used for plants, and the declining-balance method is used for all others.
However, buildings (excluding facilities attached to buildings) acquired on or after April 1, 1998
and facilities attached to buildings and structures acquired on or after April 1, 2016 are depreciated
using the straight-line method.
Overseas consolidated subsidiaries use the straight-line method.
The useful lives of major assets are as follows.
Buildings and structures
3 to 50 years
Machinery, equipment and vehicles
2 to 15 years
(2) Intangible assets (excluding leased assets)
The straight-line method is used.
Software for internal use is amortized by the straight-line method over the estimated useful life (5
years).
(3) Leased assets
Finance lease transactions that do not transfer ownership are depreciated using the straight-line
method over the lease period with a residual value of zero.
(4) Long-term prepaid expenses
The straight-line method is used.
(C) Accounting for significant provisions
(1) Allowance for doubtful accounts
To provide for possible bad debt expenses on trade receivables, etc. as of the end of the fiscal year
under review, an allowance for doubtful accounts is provided in the amount deemed uncollectible
based on historical bad debt ratios for general receivables and on an individual assessment of
collectibility for specific receivables for which there is concern about default.
(2) Provision for bonuses
To provide for bonuses to employees to be paid in the next and subsequent fiscal years, an amount
accrued for the fiscal year under review among the estimated future payments is recorded.
(D) Accounting for retirement benefits
(1) Method of attributing estimated retirement benefits to periods of service
The estimated amount of retirement benefits is attributed to the period until the end of the fiscal
year under review based on the benefit calculation method.
(2) Method of amortizing actuarial gains and losses and prior service cost
Prior service cost is amortized by the straight-line method over a fixed number of years (10 years)
within the average remaining service period of employees at the time the cost is incurred.
Actuarial gains and losses are amortized by the straight-line method over a fixed number of years
(10 years) within the average remaining service period of employees at the time of their accrual,
starting from the following fiscal year of accrual.
14
(3) Accounting for unrecognized actuarial gains and losses and unrecognized prior service cost
Unrecognized actuarial gains and losses and unrecognized prior service cost are recognized in
accumulated other comprehensive income under net assets, remeasurements of defined benefit
plans, after adjusting for tax effects.
(E) Basis for recording significant income and expenses
The Group’s principal business is the manufacture and sale of products and the sale of merchandise in
the Ethical Pharmaceuticals Business and Consumer Healthcare Business. For the sale of these
products and merchandise, the Group usually recognizes revenue when the products and merchandise
are inspected and accepted by the customer, since it is considered that the customer has acquired
control over the products and merchandise and the performance obligation has been satisfied when the
products and merchandise are inspected and accepted by the customer. For sales in Japan, revenue is
recognized at the time of shipment if the period between the time of shipment and the time of
acceptance by the customer is a normal period of time. Revenue is measured at the amount of
consideration promised in the contract with the customer, less any returns, discounts and rebates.
Deductions other than those for confirmed payments, such as rebates and sales incentives paid to
customers, are estimated and recognized to the extent that it is probable that a material reversal will
not occur, taking into consideration the content of the contract and past results. We identify points
granted to customers as performance obligations, allocate the transaction price based on the
independent sales price, and recognize revenue when the points are used.
The consideration for transactions is received within one year of satisfaction of the performance
obligation and does not include a significant financial component.
(F) Basis of translation of significant assets and liabilities denominated in foreign currencies into Japanese
yen
Receivables and liabilities denominated in foreign currencies are translated into yen at the spot
exchange rates prevailing on the consolidated balance sheet date, with translation differences
recognized as gains or losses. Assets and liabilities of overseas consolidated subsidiaries are translated
into yen at the spot exchange rate on the balance sheet date of the overseas consolidated subsidiaries,
and revenues and expenses are translated into yen at the average exchange rate during the accounting
period of the relevant overseas consolidated subsidiaries, with the translation differences included in
the foreign currency translation adjustments and non-controlling interests in net assets.
(G) Significant hedge accounting methods
(1) Hedge accounting methods
In principle, deferred hedge accounting is applied. Forward exchange contracts that meet the
requirements for allocation method are accounted for using the allocation method.
(2) Hedging instruments and hedged items
Forward exchange contracts are used as hedging instruments and trade payables and forecasted
import transactions denominated in foreign currencies are used as hedged items.
(3) Hedging policy
The Company uses forward exchange contracts and other hedging instruments to hedge foreign
exchange fluctuation risks of trade payables and forecasted import transactions denominated in
foreign currencies, and hedging instruments, such as forward exchange contracts, are made within
the scope of trade payables and forecasted import transactions denominated in foreign currencies
that are hedged items.
(4) Evaluation of hedge effectiveness
The evaluation of hedge effectiveness is omitted because the hedging instruments are identical to
the material terms of the hedged forecasted transactions, and it can be assumed that the hedging
instruments will completely offset the market fluctuations at the inception of the hedge and
continuously thereafter.
(H) Amortization method and period of goodwill
Goodwill of Tillotts Pharma AG, Pharmaceutical Joint Stock Company of February 3rd and ZPD A/S
is amortized by the straight-line method over 20 years.
15
(I)
Scope of cash in the consolidated statements of cash flows
Cash (cash and cash equivalents) in the consolidated statements of cash flows includes cash on hand,
deposits that can be withdrawn on demand, and short-term investments with maturities of three months
or less at the time of acquisition that are readily convertible to cash and are exposed to insignificant
risk of changes in value.
16
(Notes on segment information, etc.)
[Segment information]
- Overview of reportable segments
The Company’s reportable segments are components of the Company for which separate financial
statements are available and which are subject to periodic review by the Board of Directors in order to
determine the allocation of management resources and evaluate their performance.
The Company’s reportable segments are Ethical Pharmaceuticals Business and Consumer Healthcare
Business, as the Company’s business activities are focused on ethical and OTC drugs.
In the Ethical Pharmaceuticals Business, the Company conducts research, development,
manufacturing, and sales of ethical pharmaceuticals.
In the Consumer Healthcare Business, the Company conducts manufacturing, purchase, and sales of
OTC drugs, health foods, quasi-drugs, and cosmetics for self-medication.
- Method of calculating net sales, profit or loss, assets, liabilities and other items by reportable segment
The accounting method for reported business segments is generally the same as that described in the
“Significant matters that form the basis for the preparation of consolidated financial statements.”
Profits of reportable segments are based on operating profit (after amortization of goodwill), and
intersegment revenues and transfers are based on prevailing market prices.
- Information on net sales, profit or loss, assets, liabilities and other items by reportable segment
Previous fiscal year (April 1, 2024 to March 31, 2025)
(Thousands of yen)
Reportable segment
Adjustment
(Note 2)
Amount
recorded in
consolidated
financial
statements
(Note 3)
87,311,137
–
87,311,137
537,519
546,556
(546,556)
–
87,159,508
698,184
87,857,693
(546,556)
87,311,137
17,174,814
243,770
17,418,585
(5,220,999)
12,197,585
Other
(Note 1)
Ethical
Pharmaceutic
als Business
Consumer
Healthcare
Business
Total
58,970,905
28,179,566
87,150,472
160,664
8,926
109
9,036
Total
58,979,832
28,179,676
Segment profit
10,777,321
6,397,492
Segment assets
96,017,295
28,939,493 124,956,789
Net sales
Sales to external
customers
Intersegment sales
and transfers
Other items
Depreciation
Amortization of
goodwill
Increase in property,
plant and equipment
and intangible
assets
Total
4,900,353 129,857,142
29,314,453 159,171,596
5,770,338
855,716
6,626,055
91,295
6,717,350
125,820
6,843,170
493,500
218,020
711,521
–
711,521
–
711,521
1,973,401
375,409
2,348,810
76,479
2,425,289
449,215
2,874,505
(Notes) 1. “Other” is a business segment not included in the reportable segments and includes the insurance agency business
and real estate business.
2. (i) Adjustment of segment profit of (5,220,999) thousand yen is mainly corporate expenses, such as general and
administrative expenses that are not allocated to each reportable segment.
(ii) Adjustment of segment assets of 29,314,453 thousand yen is mainly corporate assets not allocated to each
reportable segment.
3. Segment profit is adjusted with operating profit in the consolidated financial statements.
17
Current fiscal year (April 1, 2025 to March 31, 2026)
(Thousands of yen)
Adjustment
(Note 2)
Amount
recorded in
consolidated
financial
statements
(Note 3)
89,159,262
–
89,159,262
477,793
482,756
(482,756)
–
628,717
89,642,019
(482,756)
89,159,262
201,029
18,737,333
(6,362,888)
12,374,444
Reportable segment
Net sales
Sales to external
customers
Intersegment sales
and transfers
Total
Consumer
Healthcare
Business
Total
61,625,839
27,382,499
89,008,338
150,923
4,864
98
4,963
61,630,703
27,382,598
89,013,302
18,536,303
Segment profit
12,176,084
6,360,219
Segment assets
108,802,451
30,140,937 138,943,388
Other items
Depreciation
Amortization of
goodwill
Increase in property,
plant and equipment
and intangible
assets
Other
(Note 1)
Ethical
Pharmaceutic
als Business
Total
4,874,396 143,817,785
35,880,164 179,697,949
5,733,006
678,483
6,411,489
90,498
6,501,988
127,300
6,629,288
493,466
224,435
717,902
–
717,902
–
717,902
641,143
1,791,583
2,432,726
36,747
2,469,474
572,800
3,042,275
(Notes) 1. “Other” is a business segment not included in the reportable segments and includes the insurance agency business
and real estate business.
2. (i) Adjustment of segment profit of (6,362,888) thousand yen is mainly corporate expenses, such as general and
administrative expenses that are not allocated to each reportable segment.
(ii) Adjustment of segment assets of 35,880,164 thousand yen is mainly corporate assets not allocated to each
reportable segment.
3. Segment profit is adjusted with operating profit in the consolidated financial statements.
18
[Related information]
Previous fiscal year (April 1, 2024 to March 31, 2025)
- Information by product and service
(Thousands of yen)
Ethical
pharmaceuticals
Consumer healthcare
products
58,970,905
28,179,566
Sales to external
customers
Other
Total
160,664
87,311,137
- Information by region
(1) Net sales
(Thousands of yen)
Japan
37,604,750
Europe
UK
France
11,349,456
Other
9,046,110
Other
Total
5,960,466
87,311,137
23,350,353
(Notes) 1. Net sales are based on the location of customers and are classified by country or region.
2. Major countries or regions included in each category
Other: Asia, Africa, Oceania, Latin America, and North America
(2) Property, plant and equipment
Japan
Europe
Vietnam
20,096,931
2,940,538
3,603,975
(Thousands of yen)
Total
26,641,444
Current fiscal year (April 1, 2025 to March 31, 2026)
- Information by product and service
(Thousands of yen)
Ethical
pharmaceuticals
Consumer healthcare
products
61,625,839
27,382,499
Sales to external
customers
Other
Total
150,923
89,159,262
- Information by region
(1) Net sales
(Thousands of yen)
Japan
36,318,192
Europe
UK
France
Other
12,405,758
10,174,765
24,005,304
Other
Total
6,255,241
89,159,262
(Notes) 1. Net sales are based on the location of customers and are classified by country or region.
2. Major countries or regions included in each category
Other: Asia, Africa, Oceania, Latin America, and North America
(2) Property, plant and equipment
Japan
Europe
Vietnam
(Thousands of yen)
Total
20,585,472
3,342,712
3,671,197
27,599,383
[Information on impairment losses on fixed assets by reportable segment]
Previous fiscal year (April 1, 2024 to March 31, 2025)
Not applicable.
Current fiscal year (April 1, 2025 to March 31, 2026)
Not applicable.
19
[Information on amortization of goodwill and unamortized balance by reportable segment]
Previous fiscal year (April 1, 2024 to March 31, 2025)
(Thousands of yen)
Amortization for the
fiscal year
Balance at end of period
Ethical
Pharmaceuticals
Business
Consumer Healthcare
Business
493,500
218,020
–
711,521
2,352,832
1,268,338
–
3,621,171
Other
Total
Current fiscal year (April 1, 2025 to March 31, 2026)
(Thousands of yen)
Amortization for the
fiscal year
Balance at end of period
Ethical
Pharmaceuticals
Business
Consumer Healthcare
Business
493,466
224,435
–
717,902
1,859,024
1,168,482
–
3,027,507
[Information on gain on bargain purchase by reportable segment]
Previous fiscal year (April 1, 2024 to March 31, 2025)
Not applicable.
Current fiscal year (April 1, 2025 to March 31, 2026)
Not applicable.
20
Other
Total
(Notes on per share information)
Previous fiscal year
(April 1, 2024 to March 31, 2025)
Net assets per share
(Yen)
Current fiscal year
(April 1, 2025 to March 31, 2026)
2,031.33
2,459.12
225.42
191.80
Profit per share
(Notes) 1. Diluted profit per share is not shown in the above table, as there are no dilutive shares.
2. Basis for calculation of net assets per share is as follows.
End of previous fiscal year
(March 31, 2025)
Item
End of current fiscal year
(March 31, 2026)
Total net assets (thousand yen)
89,797,027
108,604,790
Amount deducted from total net
assets (thousand yen)
257,189
208,048
[Of which, non-controlling
interests (thousand yen)]
[257,189]
[208,048]
Net assets related to common shares
at the end of the period (thousand
yen)
89,539,838
108,396,741
Number of common shares issued
and outstanding (shares)
53,119,190
50,119,190
Number of treasury common shares
(shares)
9,039,667
6,039,792
Number of common shares used for
calculation of net assets per share
(shares)
44,079,523
44,079,398
Previous fiscal year
(April 1, 2024 to March 31, 2025)
Current fiscal year
(April 1, 2025 to March 31, 2026)
Profit attributable to owners of parent
(thousand yen)
9,936,323
8,454,544
Profit attributable to owners of parent
related to common shares (thousand
yen)
9,936,323
8,454,544
Average number of common shares
during the period (shares)
44,079,600
44,079,460
- Basis for calculation of profit per share is as follows.
Item
(Notes on significant subsequent events)
Not applicable.
21
- Supplemental Information
(1) Sales of major products and merchandise Consolidated
(Thousands of yen)
Previous fiscal year
(from April 1, 2024
to March 31, 2025)
- Ethical Pharmaceuticals
Business
58,970,905
Current fiscal year
(from April 1, 2025
to March 31, 2026)
Percentage change
(%)
61,625,839
4.5
Asacol
23,565,885
24,302,532
3.1
DIFICLIR
20,764,118
22,587,507
8.8
(2.4)
Entocort
5,372,490
5,246,152
Acofide
3,040,136
3,079,985
1.3
Other
6,228,274
6,409,661
2.9
- Consumer Healthcare
Business
28,179,566
27,382,499
(2.8)
Hepalyse range
12,552,741
13,254,664
5.6
Chondroitin range
5,572,999
5,427,285
(2.6)
WithOne range
1,530,314
1,460,020
(4.6)
Other
8,523,511
7,240,529
(15.1)
- Other Business
160,664
150,923
(6.1)
Total
87,311,137
89,159,262
2.1
22
(2) Status of pipeline of new drugs
I.
Domestic
As of May 8, 2026
Stage
Development Code/
Generic Name
Development
Indications
Classification
Origin
Phase III
Z-338/Acotiamide
Zeria
Pediatric functional
dyspepsia
Upper gastrointestinal
motility modulator
Original
Phase II
ZG-802/Acotiamide
Zeria
Underactive bladder
Lower urinary tract
function modulator
Original
Nonprofit
Organization,
Non-small cell lung
North East
cancer
Japan Study
Group
Immunomodulator
Original
Phase II
(Specified Clinical
Trial)
Z-100
II. Overseas
Stage
Development Code/
Generic Name
Development
Indications
Classification
Origin
NDA approved
(Nicaragua,
Costa Rica)
Z-338/Acotiamide
Faes Farma
Functional
dyspepsia
Upper gastrointestinal
motility modulator
Original
(Out-licensed)
NDA filed
(Vietnam)
Z-338/Acotiamide
Pharmaceutical
Joint Stock
Company of
February 3rd
Functional
dyspepsia
Upper gastrointestinal
motility modulator
Original
NDA filed
(Colombia,
Panama)
Z-338/Acotiamide
Faes Farma
Functional
dyspepsia
Upper gastrointestinal
motility modulator
Original
(Out-licensed)
Phase III
(Europe, United
States, Canada)
Z-338/Acotiamide
Agastra-Lab
s.r.l.
Functional
dyspepsia
Upper gastrointestinal
motility modulator
Original
(Out-licensed)
23